Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
Holding IDYA?
Track your performance easily
IDYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.20 - $47.74
Previous Close$26.6
Volume2.10M
Average Volume (3M)766.78K
Market Cap
$2.30B
Enterprise Value$1.40B
Total Cash (Recent Filing)$920.03M
Total Debt (Recent Filing)$18.80M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Apr 01, 2025EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding86,431,799
10 Day Avg. Volume774,069
30 Day Avg. Volume766,778
Standard Deviation0.21
R-Squared0.05
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.87
Price to Sales (P/S)569.75
Price to Cash Flow (P/CF)-11.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue356.32
Enterprise Value/Gross Profit59.78
Enterprise Value/Ebitda-7.48
Forecast
1Y Price Target
$54.57Price Target Upside103.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
IDEAYA Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe registrational Ph 2/3 trial of darovasertib and crizotinib in 1L MUM is enrolling ahead of schedule with potential to accelerate further with addition of ex-US sites.
Financial PositionIDYA reported cash, equivalents, and marketable securities of $1.2B, providing a strong financial position.
Pipeline DevelopmentIDYA's pipeline includes darovasertib in neoadjuvant uveal melanoma, which is seen as a potential blockbuster opportunity, showing significant growth potential.
Bears Say
Clinical TrialsThe trial for darovasertib in frontline HLA- metastatic uveal melanoma is unlikely to have an interim readout until around 2026, causing a limbo in the near/intermediate term.
Market CompetitionPotential competition from AURA's bel-sar in neoadjuvant patients with small tumors may impact Ideaya Biosciences' total addressable market.
Regulatory ChallengesMuted stock reaction is due to confusion around timelines to approval and lack of a formal go-ahead for accelerated approval from the FDA.
---
Ownership Overview
0.89% Insiders
33.15% Mutual Funds
33.95% Other Institutional Investors
18.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IDYA FAQ
What was IDEAYA Biosciences’s price range in the past 12 months?
IDEAYA Biosciences lowest stock price was $25.20 and its highest was $47.73 in the past 12 months.
What is IDEAYA Biosciences’s market cap?
Currently, no data Available
When is IDEAYA Biosciences’s upcoming earnings report date?
IDEAYA Biosciences’s upcoming earnings report date is Apr 01, 2025 which is in 129 days.
How were IDEAYA Biosciences’s earnings last quarter?
IDEAYA Biosciences released its earnings results on Nov 04, 2024. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.648 by $0.048.
Is IDEAYA Biosciences overvalued?
According to Wall Street analysts IDEAYA Biosciences’s price is currently Undervalued.
Does IDEAYA Biosciences pay dividends?
IDEAYA Biosciences does not currently pay dividends.
What is IDEAYA Biosciences’s EPS estimate?
IDEAYA Biosciences’s EPS estimate is -$0.62.
How many shares outstanding does IDEAYA Biosciences have?
IDEAYA Biosciences has 86,431,800 shares outstanding.
What happened to IDEAYA Biosciences’s price movement after its last earnings report?
IDEAYA Biosciences reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.648. Following the earnings report the stock price went up 4.895%.
Which hedge fund is a major shareholder of IDEAYA Biosciences?
Among the largest hedge funds holding IDEAYA Biosciences’s share is Deerfield Management Company, LP. It holds IDEAYA Biosciences’s shares valued at 82M.
---
IDEAYA Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.57 (103.70% Upside)
$54.57 (103.70% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.78%
12-Months-Change
Fundamentals
Return on Equity
-21.10%
Trailing 12-Months
Asset Growth
132.65%
Trailing 12-Months
Company Description
IDEAYA Biosciences
IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
---
IDYA Stock 12 Month Forecast
Average Price Target
$54.57
▲(103.70% Upside)
Technical Analysis
Best Analysts Covering IDYA
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+42.36%
reiterated a buy rating 25 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +42.36% per trade.
---